The liver is the body’s principal chemical processing centre, responsible for transforming nutrients, hormones and foreign substances. It also produces enzymes that can convert apparently harmless compounds into reactive metabolites capable of damaging cells. Conventional toxicity screens often rely on immortalised liver cancer cell lines or isolated animal cells, models that may not reproduce the enzyme activity, cellular organisation and stress responses of human liver tissue. Human pluripotent stem cells offer a potential alternative because they can generate hepatocyte-like cells, but cells produced in the laboratory frequently remain developmentally immature, resembling fetal rather than adult liver cells.

The study focuses on liver spheroids, three-dimensional clusters in which liver-derived cells interact with one another and organise into a tissue-like structure. Compared with flat, two-dimensional cultures, spheroids can maintain more physiologically relevant cell contacts, gradients of oxygen and nutrients, and longer-term responses to chemical exposure. Their three-dimensional architecture may also help preserve functions that tend to disappear rapidly when hepatocytes are spread across a plastic surface. Yet structure alone is not enough. If the cells inside a spheroid remain immature, the model may still fail to reproduce the metabolic pathways that determine whether a compound is detoxified, tolerated or converted into a harmful product.

The six-compound cocktail is intended to push stem-cell-derived liver cells through that developmental bottleneck. In principle, such a mixture can act on several biological pathways at once, including signalling networks that regulate hepatic identity, metabolic enzyme expression, cell polarity and tissue organisation. The challenge is to find a combination that promotes adult-like function without causing excessive stress, uncontrolled growth or an artificial state that exists only in culture. Rather than treating maturation as the effect of a single “master switch,” the approach recognises that liver development is coordinated by multiple molecular cues operating over time.

A mature liver model must do more than produce characteristic proteins. It should also demonstrate functional activity, such as the ability to process drugs, regulate secreted molecules, handle lipids and respond to toxic insults in a reproducible manner. Researchers developing these systems typically examine markers of hepatocyte identity alongside enzymes involved in phase I and phase II metabolism, transport proteins and cellular responses associated with injury. These measurements help distinguish between cells that merely resemble hepatocytes and cells that perform the specialised biochemical work expected of human liver tissue.

That distinction is crucial for toxicity prediction. A drug can appear safe in an immature culture because the enzymes needed to metabolise it are absent or expressed at unusually low levels. The same compound may produce a very different result in a more mature system, particularly if metabolism generates reactive intermediates. Conversely, an immature model might overestimate toxicity by failing to reproduce protective detoxification pathways. By improving the functional maturity of liver spheroids, the cocktail could make laboratory results more closely aligned with how human tissue handles chemical exposure, although the practical value depends on the consistency and validation of the resulting model.

The researchers’ strategy also speaks to a broader shift in biomedical testing away from simple cell survival measurements. Toxicity is not defined solely by whether cells die immediately. Liver injury can involve oxidative stress, mitochondrial dysfunction, impaired bile transport, inflammation-like signalling, disruption of lipid metabolism and delayed changes in gene expression. Three-dimensional stem-cell-derived models offer an opportunity to track these processes over longer periods and at multiple biological levels. Such information may reveal harmful effects that are missed by short, single-endpoint assays, while also helping researchers determine whether a response is specific to a particular chemical or reflects general culture stress.

The potential applications extend beyond pharmaceutical development. A reliable human liver spheroid platform could be used to compare candidate medicines before clinical trials, investigate why some compounds cause liver injury in only a subset of patients, and assess the effects of pesticides, food additives, cosmetics ingredients and emerging contaminants. It could also support efforts to reduce reliance on animal testing, especially when human-specific metabolism is central to the question. However, stem-cell-derived systems do not automatically reproduce the full complexity of a living liver. They may lack blood flow, immune cells, supporting stromal cells and the communication between the liver and other organs that can influence toxicity.

For that reason, the significance of the six-compound cocktail will ultimately rest on rigorous benchmarking. The model must show that its molecular signatures, metabolic behaviour and toxicological responses are stable across different stem-cell lines, laboratories and batches of spheroids. It must also be tested against chemicals with well-established human safety profiles and known liver toxicity, allowing researchers to measure both false alarms and missed hazards. If the system performs consistently under those conditions, it could become a valuable bridge between early laboratory screening and clinical risk assessment. The work offers a technically focused route toward more human-relevant toxicity testing: not simply growing liver-like cells, but guiding them toward a state in which their chemistry, organisation and response to injury more faithfully reflect the adult organ.

Subject of Research: Maturation of human pluripotent stem cell-derived liver spheroids for improved toxicity prediction.

Article Title: Six-compound cocktail for maturation of human pluripotent stem cell-derived liver spheroids for toxicity prediction.

Article References: Tian, L., Anas, F.H., Hasselkus, R. et al. “Six-compound cocktail for maturation of human pluripotent stem cell-derived liver spheroids for toxicity prediction.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76936-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76936-z

Keywords: Human pluripotent stem cells, liver spheroids, hepatocyte maturation, liver toxicity, drug safety, three-dimensional cell culture, toxicology, organoid models.

A breakthrough approach to resolving this translational gap has now been pioneered by a research team led by Professor Sanguk Kim at POSTECH’s Department of Life Sciences and Graduate School of Artificial Intelligence. This multidisciplinary team, including Dr. Minhyuk Park, Mr. Woomin Song, and Mr. Hyunsoo Ahn, has developed an innovative machine learning framework that leverages biological differences between species to forecast drug toxicity more accurately in humans. Their findings, recently published in the prestigious journal eBioMedicine, set a new standard for preclinical drug safety evaluation by focusing on the fundamental genotype-phenotype disparities that exist between humans and experimental models.

At the core of this novel methodology is the concept of “Genotype-Phenotype Difference” (GPD)—the inherent biological variations between genomes and resulting phenotypes across species. Recognizing that genetic targets of drugs regulate cellular behavior differently in animal models compared to humans, the team constructed a predictive system that integrates three pivotal biological dimensions: gene essentiality, tissue-specific gene expression patterns, and gene network connectivity. Gene essentiality reflects the criticality of gene function for cell survival; tissue-specific expression profiles determine where and how genes operate within different biological contexts; and network connectivity maps the complexity of gene interactions that underpin functional pathways.

Empirical validation of the model was conducted on an extensive dataset encompassing 434 drugs flagged as hazardous and 790 drugs that successfully passed human trials. The results revealed a robust association between GPD attributes and clinical drug failure due to toxicity. Remarkably, the machine learning model demonstrated a substantial leap in predictive accuracy relative to traditional chemical structural analyses of drugs. Quantitatively, the model improved the area under the precision-recall curve (AUPRC) from 0.35 to 0.63 and achieved a receiver operating characteristic area under the curve (AUROC) of 0.75, compared to a near-chance 0.50 baseline for conventional approaches. This indicates a significant reduction in false positives and an enhanced ability to identify truly toxic therapeutics.

Beyond just retrospective assessment, the team put their AI framework to a stringent chronological validation test. By training the model exclusively on drug data available up to 1991, it successfully predicted, with 95% accuracy, drugs that were subsequently withdrawn from the market post-1991 due to unforeseen toxicity. This temporal robustness underscores the practical utility of the model in real-world drug surveillance and early safety screening, enabling pharmaceutical companies to flag at-risk candidates before costly and ethically fraught human trials commence.

This research marks a transformative step forward by scientifically quantifying and incorporating interspecies biological differences that have been largely overlooked or difficult to model within existing drug development pipelines. Traditionally, translational failures stem from oversimplified assumptions that animal model responses directly reflect human biology. However, the nuanced genotype-phenotype relationships encoded within each species’ genome influence cellular responses to pharmacological agents in a context-dependent manner, which this framework elucidates and harnesses to refine predictions of drug safety.

By adopting this GPD-centric approach, pharmaceutical research and development can realize multiple benefits. First, it promises to considerably diminish the pipeline attrition rate caused by late-stage toxicity, which is a major contributor to exorbitant costs, time delays, and ethical concerns in drug discovery. Second, it offers a mechanism to safeguard patients by preemptively identifying pharmaceuticals likely to cause harmful side effects upon human exposure. Third, as biological datasets continue to expand—spanning genomic annotations, transcriptomic profiles, and protein interaction networks—the predictive reliability and scope of this model are poised to grow exponentially.

Professor Sanguk Kim emphasized the pioneering nature of their work, noting, “This is the first attempt to incorporate differences in genotype-phenotype relationships for drug toxicity prediction. Our framework enables early identification of high-risk drugs in clinical development.” Co-first authors Dr. Minhyuk Park and Mr. Woomin Song echoed the practical impact: “The human-centered toxicity prediction model will be a very practical tool in new drug development. We anticipate that pharmaceutical companies will be able to screen out high-risk drugs in advance at the preclinical stage, thereby improving development efficiency.”

The strategic integration of advanced machine learning with deep biological insights represented by this study exemplifies the future direction of translational medicine and computational biology. Moving beyond purely chemical descriptors, this approach navigates the complex systems biology underlying drug responses across species, opening avenues towards more reliable and ethical drug discovery processes. Moreover, this method aligns with the overarching imperative of precision medicine—tailoring therapeutic strategies to the unique biological contexts of individual patients, beginning with a better understanding of species-specific genetic and phenotypic nuances.

Supported by the National Research Foundation of Korea, the Ministry of Science and ICT, the Medical Device Innovation Center, and the Synthetic Biology Human Resources Development Program, this research serves as a pioneering example of how interdisciplinary collaboration can accelerate medical innovation. By bridging the critical translational gap, this technology not only has the potential to revolutionize pharmaceutical pipelines worldwide but also offers hope for safer, more effective therapeutics that benefit patients globally.

As the pharmaceutical industry increasingly adopts such sophisticated machine learning tools, the hope is that catastrophic clinical trial failures will become a rarity rather than a distressing norm. Ultimately, this innovative framework underscores the vital role of understanding biological diversity and leveraging computational power, offering a paradigm shift in predicting drug toxicity and safeguarding human health.

Subject of Research: Drug toxicity prediction and genotype-phenotype differences between preclinical models and humans.

Article Title: Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans

News Publication Date: 28-Oct-2025

Web References: DOI Link

Image Credits: POSTECH

Keywords: Health and medicine, Drug therapy, Drug safety, Clinical medicine, Translational research, Translational medicine, Species interaction, Adaptive systems, Artificial intelligence, Deep learning, Computer science, Machine learning, Biological models, Animal models